title: Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients.
abstract: The aim of this study was to assess the immunogenicity of a vaccine against this virus in a prospective cohort of transplanted pediatric patients without previous influenza infection who received one dose of MF59®-adjuvanted pandemic H1N1/2009 vaccine. Seventeen patients who were being regularly followed up at the Outpatient Clinic of the Children's Transplant Unit (liver and kidney transplantation) in Hospital Universitari Vall d'Hebron (Barcelona) were included. Seroconversion was demonstrated in 15 of 17 (88.2%) vaccinated children. There were no rejection episodes or major adverse events. The MF59(®) -adjuvanted pandemic H1N1/2009 vaccine was safe and elicited an adequate response.
authors.affiliation: Department of Infectious Diseases, Universitat Autònoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain. joan.gavalda@vhir.org
authors.forename: J
authors.initials: J
authors.lastname: Gavaldà
authors.forename: E
authors.initials: E
authors.lastname: Cabral
authors.forename: P
authors.initials: P
authors.lastname: Perez-Romero
authors.forename: O
authors.initials: O
authors.lastname: Len
authors.forename: T
authors.initials: T
authors.lastname: Aydillo
authors.forename: M
authors.initials: M
authors.lastname: Campins
authors.forename: J
authors.initials: J
authors.lastname: Quintero
authors.forename: M
authors.initials: M
authors.lastname: Peghin
authors.forename: J
authors.initials: J
authors.lastname: Nieto
authors.forename: R
authors.initials: R
authors.lastname: Charco
authors.forename: A
authors.initials: A
authors.lastname: Pahissa
authors.forename: E
authors.initials: E
authors.lastname: Cordero
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007251:Influenza, Human / Q000517:prevention & control*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008297:Male; D061214:Patient Safety; D011136:Polysorbates / Q000008:administration & dosage; D011446:Prospective Studies; D013185:Squalene / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene